Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment

Canadian Veterinary Journal

Volumn 50, Issue 5, 2009, Pages 506-510

  De M Souza, Carlos H ^a,b   Toledo Piza, Evandro ^a   Amorin, Renee ^a   Barboza, Andrigo ^a   Tobias, Karen M ^a  

^a Instituto Nacional de Proteção Industrial INPI   (Brazil)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

CYCLOOXYGENASE 2; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; CARCINOMA; DISEASE COURSE; DOG; DOG DISEASE; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ANIMALS; CARCINOMA; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM STAGING; PIROXICAM; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650116221     PISSN: 00085286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: Rev Clin Oncol 1992;10:1014-1024.
2. Perez-Alenza MD, Tabañera H, Pena L. Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 2001;219: 1110-1114.
3. Susaneck SJ, Allen TA, Hoopes J, Withrow SJ, Macy DW. Inflammatory mammary carcinoma in the dog. J Am Anim Hosp Assoc 1983;19: 971-976.
4. Pena L, Perez-Alenza D, Rodriguez-Bertos A, Nieto A. Canine inflammatory mammary carcinoma: Histopathology, immunohistochemistry, and clinical implications of 21 cases. Breast Can Res Treat 2003;78: 141-148.
5. Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc 2005;227:1625-1629.
6. Janne PA, Mayer RJ. Primary care. Chemoprevention of colorectal cancer. New Engl J Med 2000;342:1960-1968.
7. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochem Biophys Acta 2002;l470:M79-88.
8. Thun MJ, Henley SJ, Patrono C. Non-steroidal anti-inflammatory drugs as anti-cancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Can Inst 2002;94:252-266.
9. Knapp DW, Richardson RC, Bottoms GD, Teclaw R, Chan TCK. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
10. Mohammed SI, Khan KNM, Sellers RS, et al. Expression of cyclooxygenase-1 and 2 in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2004;70:479-483.
11. Howe LR. Cyclooxygenase and prostaglandin signaling and breast cancer. Breast Can Res 2007;9:1-9.
12. Dore M, Lanthier I, Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 2003;40:207-212.
13. Heller DA, Clifford CA, Goldschmidt MH, et al. Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol 2005;42:776-780.
14. Milanta F, Citi S, Delia Santa D, Porciani M, Poli A. Cox-2 expression in canine and feline invasive mammary carcinomas: Correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat 2006;98:115-120.
15. Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes C, Illera JC. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: Clinicopathological features and prognostic significance. Anticancer Res 2005;25(6B):4269-4275.
16. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
17. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783-1786.
18. Cariati M, Bennett-Britton TM, Pinder AD, Purushotam AD. Inflammatory breast cancer. Surg Oncol 2005;14:133-143.
19. Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 2003;5:284-288.
20. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: Clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-429.
21. Simon D, Shoenrock D, Baumgärtner W, Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006;20:1184-1190.
22. Wardley A. Capecitabine: Expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist 2006;ll(Suppl l):20-26.
23. Harris EER, Schultz D, Bertsch H, et al. Int J Radiation Oncology Biol Phys 2003;5:1200-1208.
24. Queiroga FL, Alves A, Pires I, Lopes C. Expression of Cox-1 and Cox-2 in canine mammary tumors. J Comp Pathol 2007;136:177-185.
25. Brunelle M, Sartin EA, Wolfe LG, et al. Cyclooxygenase expression in normal and neoplastic canine mammary cell lines. Vet Pathol 2006;43:656-666.
26. Mutsaers AJ, Mohammed SI, DeNicola DB, et al. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot Essent Fatty Acids 2005;72:181-186.
27. Knottenbelt C, Chambers G, Gault E, Argyle DJ. The in vitro effects of piroxicam and meloxicam on canine cell lines. J Small Anim Pract 2006;47:14-20.